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Chemically synthesized ligands for nuclear receptors of the PPAR family modulate a number of physiological functions,
particularly insulin resistance in the context of energy homeostasis and the metabolic syndrome. Additionally, these compounds
may treat or prevent the development of many secondary consequences of the metabolic syndrome. Many PPAR agonists are
also known to inﬂuence the proliferation and apoptosis of breast carcinoma cells though the experiments were carried out at
suprapharmacological doses of PPAR ligands. It is possible that the breast epithelium of diabetics exposed to PPAR agonists will
experience perturbation of the corresponding signaling pathway. Consequently, these patients’ lifetime breast carcinoma risks
could be modiﬁed, as their breast lesion incidence or the rates of the conversion of these lesions to carcinomas might vary upward
or downward. PPAR activating treatment may also inﬂuence the progression of existing, undiagnosed invasive lesions. In this
review, we attempt to summarize the possible inﬂuence of chemical PPAR ligands on the molecular pathways involved in the
initiation and progression of breast carcinoma, with a major emphasis on PPARγ agonists thiazolidinediones (TZDs).
Copyright © 2008 Ancha Baranova. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1. INTRODUCTION
Breast carcinoma is the most common nonskin cancer
among women worldwide, responsible for about 375000
d e a t h sp e ry e a r[ 1]. The probability of the development of
breast carcinoma increases before menopause (ages 40–50)
and then gradually decreases, possibly due to diminishing
levels of circulating estrogens [2]. In developed countries,
the prevalence of breast carcinoma is higher due to the
frequency of known risk factors for the disease, including
early age at menarche, nulliparity, late age at ﬁrst birth,
late menopause, and brief duration of breastfeeding [2].
All of these risk factors are tightly linked to hormonal
background, particularly to lifelong exposure of breast tissue
to endogenous estrogens [3]. Exogenous factors inﬂuencing
breastcarcinomadevelopmentincludetheuseoforalcontra-
ceptives [4] and hormone replacement therapy [5, 6]a sw e l l
as dietary or lifestyle-related variables. The latter category
is rather vague, as it includes many factors detrimental to
general health, such as high body-mass index [7], high fat
intake [8], high red meat consumption [9], excessive alcohol
consumption [10], and reduced physical activity [11].
A number of chemoprevention strategies for breast
carcinoma are developed or under development. The note-
worthy example is a tamoxifen chemoprevention in high-
risk premenopausal women, which heralded the success of
selective estrogen receptor modulators (SERMs) [12]. A new
agent, raloxifene (Evista, Eli Lilly, IN, USA) also competes
with endogenous estrogen for ER binding and shows similar
promises with fewer side eﬀects [13]. Interestingly, many
potential breast carcinoma preventive agents studied earlier
are also available over-the-counter and widely used by target
populations. Examples of this kind include aspirin [14], soy
isoﬂavones [15], and Vitamin D [16].
Recently, the universe of chemical compounds com-
monly encountered by current and future breast carcinoma
patients has been enriched by a number of pharmacother-
apeutic agents being prescribed as a lifelong support for
common chronic diseases. Depending on the particular
molecular pathways which these agents modulate, they may
contribute to initial immortalization of breast epithelia,
stimulate proliferation and invasion of existing tumor cells,
or on the contrary, prevent the tumor’s development. For
example, type II diabetes patients are routinely treated with2 PPAR Research
chemically synthesized ligands for PPARγ, thiazolidine-
dione (TZD), namely pioglitazone (Actos, Takeda/Lilly),
and rosiglitazone (Avandia, GlaxoSmithKline). The glucose-
lowering eﬀects of these compounds are mediated primarily
by decreasing insulin resistance and increasing glucose
uptake by the skeletal muscles [17]. In addition, TZDs
suppress glucose production in the liver [17]. These and
other beneﬁcial eﬀects rapidly made TZDs a mainstream
diabetes therapy [18].
In addition to their antidiabetic eﬀects, TZDs are known
to suppress the proliferation and induce apoptosis of breast
carcinoma cells in vitro [19, 20]. It is likely that the breast
epithelium of diabetics exposed to TZDs will also experience
perturbation of the PPAR signaling pathway. Consequently,
current or past TZD users’ lifetime breast carcinoma risks
may be modiﬁed, as their breast lesion incidence or rates of
the conversion of these lesions to carcinomas might change
upward or downward. TZD treatment may also inﬂuence the
progression of existing undiagnosed invasive lesions.
In addition to PPARγ ligands, PPARα [21]a n dP P A R δ
[22] are currently being explored as potential cardiovascular
therapeutics and metabolic syndrome alleviation agents. If
these agents will be approved by FDA, it is very possible
that in the next two or three decades the number of women
exposed to one or another type of PPAR ligands may reach
10–15 million in the USA alone. Possible modiﬁcations of
the breast carcinoma incidence and outcomes resulted by the
chronic exposure to these compounds might translate into
statistically signiﬁcant changes visible in epidemiological
survey data, similar to those seen in cohorts taking hormone
replacement therapy [5, 6].
In this review, we attempt to summarize the possible
inﬂuence of chemical PPAR ligands on the molecular
pathways involved in the initiation and progression of breast
carcinoma. Major emphasis will be on PPARγ,a ss m a l l
molecular agonists of this nuclear receptor are widely used
in the treatment of type II diabetes all over the world.
2. PPARγ LIGANDS
A gene encoding nuclear hormone receptor, PPARγ, express-
es as two diﬀerent mRNA isoforms derived from the
alternative promoters, ubiquitous PPARγ1 and adipose-
speciﬁc PPARγ2[ 23]. Both isoforms stimulate adipogenesis;
however,PPARγ2canbeactivatedbylowerconcentrationsof
ligands [23]. Activated PPARγ heterodimerizes with various
coactivators[24,25],whichmodulatetheexpressionofgenes
with promoters containing bi-hexametric PPRE elements.
These elements are widespread in the human genome, being
present in both fatty acid metabolism and cell cycle control
genes [26]. Moreover, the list of targets directly regulated by
PPARγ includes many genes which lack PPRE [27]. Most
likely, this is due to either the binding of activated PPARγ
to other proteins that, in turn, serve as transcription factors
(TFs) or the action of PPRE-containing genes providing
delayed transcriptional response to PPARγ ligation [27].
Knowledge about endogenous ligands for PPARγ is limited.
The list of these compounds includes polyunsaturated fatty
acids (PUFAs) and eicosanoids, particularly lipoxygenase
(LOX), and cyclooxygenase (COX) products [28]. An anti-
inﬂammatory prostaglandin, 15-deoxy-D12,14-PGJ2 (15d-
PGJ2), which is formed from PGD2 in vivo, is probably
the most potent endogenous PPARγ ligand [28]. Another
powerful physiological stimulator of PPARγ is oxidized
phosphatidylcholine [29]. It should be mentioned that
synthetic ligands of PPARγ (TZDs) display stronger binding
aﬃnity to this nuclear receptor than its endogenous ligands,
thus raising the question whether the list of natural PPARγ
ligands is complete.
2.1. Effectsofthechronicexposureofthebreast
epitheliumtoPPARγ agonists
PPARγ is expressed in normal breast tissue and in many
primary breast carcinoma specimens [30, 31]. Comparative
studies of PPARγ expression in breast carcinoma patients so
far have produced contradictory results [32–34]. Described
associations between PPARG polymorphisms and breast car-
cinomaarealsodiscrepant:someresearchersseeamarginally
signiﬁcantincreaseintheriskofbreastcanceramongwomen
homozygous for the Ala allele of PPARγ (Pro12Ala), causing
a reduction in the transcriptional activity of PPARγ2[ 35],
while others stress that carriers of the same variant allele are
at lower risk [36] .S i n c ec o m p l e t el o s so fP P A R γ signaling in
clinical breast tumors seems to be a rare event [37], it is likely
that patients undergoing chronic treatment with chemical
ligands for PPARγ will experience alteration in the behavior
ofbothbreastcarcinomacellsandtheirnormalcounterparts.
Patients with ER-positive tumors might beneﬁt from TZD
exposure more than those with ER-negative tumors, as the
level of PPARγ expression is signiﬁcantly associated with the
ER status of carcinoma cells [38].
Chemically synthesized ligands for PPARγ (thiazolidine-
diones, or TZDs) have actively been used as insulin
sensitizers since the late 90s [18]. In addition to their
insulin resistance-alleviating eﬀects, TZDs may inﬂuence an
incidenceoraprogressionofbreastcarcinomalesionsasthey
have been shown to suppress the proliferation rates of many
types of cancer cells and induce either their diﬀerentiation
or apoptosis in vitro [20, 39, 40]. Responsiveness to TZDs
has been demonstrated for both normal human mammary
epithelial cells [30] and breast cancer cells [41–43], although
itwasnotuniformlyseeninallexperimentalconditions[44].
TZDs suppress the cell cycle by repressing cyclins D1 and D3
[45], by stimulating expression of the tumor suppressor p53
and its eﬀector p21 (WAF1/Cip1) [46], and by inhibiting the
Akt/PTEN pathway [47]. Additionally, TZDs induce marked
cellular acidosis in breast carcinoma cell lines, leading to a
decrease in the number of viable cells [48]. Some eﬀects
of TZDs are independent of the transcriptional activities
of PPARγ [48]; these eﬀects may be mediated through
interactions of these compounds with other cellular targets.
The growth-suppressive properties of TZDs are comple-
mented by their ability to induce apoptosis. Many breast
tumors are naturally resistant to the apoptotic action of
the tumor necrosis factor-related apoptosis-inducing ligand
(TRAIL) and other similar agents. TZDs sensitize these cells
to TRAIL [45], to anti-Fas IgM (CH11), and to tumorAncha Baranova 3
necrosis factor (TNF)-α [49]. It is tempting to speculate
that TZDs might prevent the spread of microscopic breast
tumors by sensitizing malignant cells to these endogenous
apoptotic signals. Interestingly, TZDs also synergize with all-
trans-retinoic acid (ATRA) to induce apoptosis in MCF-7
and primary breast carcinoma cells, but not in the normal
breast epithelium [43]. Some TZDs also stimulate expression
of apoptosis related genes, such as growth arrest and DNA
damage-inducible gene 45 (GADD45)[ 50], BRCA1 [51]a n d
proline oxidase encoding gene POX [52]. In addition to
intrinsic apoptotic pathways, TZDs are also capable of the
direct stimulation of the FASL gene encoding Fas ligand that
induces an apoptosis by cross-linking with the Fas receptor
located on the membranes of the adjacent cells [53].
Additionally, TZDs block the invasion of tumor cells
through upregulation of the tissue inhibitor of MMP-
1/TIMP-1 and a subsequent decrease in MMP-9 gelatinolytic
activities [54] .T h e s eo b s e r v a t i o n sh a v eb e e ns u p p o r t e db y
experiments with the murine mammary tumor cell line
LMM3, which produces less metastatic nodules in lungs
of animals treated by oral rosiglitazone [55]. It should be
mentioned that the pronounced antitumor eﬀects described
above occur only at suprapharmacological doses of TZDs. It
remains to be seen whether chronic exposure to TZDs could
have therapeutic eﬀects in patients with established breast
tumors.
The eﬀects described above are relevant only to some
TZD users, namely, patients currently with breast tumors
and those diagnosed with such tumors in the past. It is still
unclear whether action of PPARγ ligands is diﬀerent within
normal and tumor cells, and what would be eﬀects of TXD
exposure in cancer free individuals. There are some indica-
tions that PPARγ ligands may inﬂuence the initial stages of
breast carcinoma development, in particular, immortaliza-
tion of the breast epithelia. One recent study demonstrated
that exposure to low nontoxic doses of rosiglitazone (10nM)
reduces the frequency of spontaneous immortalization of
Li-Fraumeni syndrome (LFS)-derived (p53 +/−,t e l o m e r a s e
silent) breast epithelial cells by almost four times [56]. In
these experimental settings, the antimutagenic properties of
this widely prescribed TZD were superior to those of well-
known chemopreventive agents such as sulindac sulﬁde and
celecoxib [56]. It will be interesting to see whether exposure
to TZD is capable of lowering the incidence of malignant
foci in the breast epithelia genetically predisposed to breast
carcinoma development, particularly that of carriers of
mutations in BRCA, BRCA2, or ATM.
Some eﬀects outlined above result from the interference
of PPARγ signaling with other pathways involved in breast
carcinogenesis, particularly with estrogen receptor (ER)α
and NF-κB cascades. Agonists of PPARγ may suppress
NF-κB dependent transcription either through an increase
in physical interaction between PPARγ and p65 [57]o r
through SUMOylation-dependent targeting of PPARγ to
NCoR/histone deacetylase-3 (HDAC3) corepressor com-
plexes which prevent NCoR/HDAC3 clearance from NF-κB
target gene promoters [58]. The interplay between ER and
PPARγ signaling seems to be more complex. Many PPARγ
ligands,particularlytroglitazoneandciglitazone,inhibitERα
signaling by stimulating proteasomal degradation of ERα
[59].
On the other hand, one recent study’s ﬁndings are
disturbing: in the breast cancer cell line MCF-7, commonly
used as a model for ER-positive breast carcinoma, TZD
rosiglitazone has been shown to induce both estrogen
receptorresponseelementactivityandcellproliferation[44].
Even more disturbing is the fact that in dose-response assays
higher concentrations of rosiglitazone inhibited prolifera-
tion, while lower concentrations of the same compound
induced proliferation. Rosiglitazone-induced proliferation
and ERE reporter activation were mediated by ERα and the
extracellular signal-regulated kinase-mitogen activated pro-
tein kinase (ERK-MAPK) pathway [44]. The concentration-
dependent nature of rosiglitazone’s eﬀects may have tremen-
dous clinical importance for the chronic users of TZDs.
Moreover, these ﬁndings point at the possibility that the
eﬀects of the rosiglitazone might vary between individuals,
as the bioavailability of rosiglitazone depends on the activity
of the CYP2C9 and CYP2C8 enzymes [60], which are
substantially polymorphic in human populations.
2.2. ChronicexposuretoPPARγ agonists
inﬂuencesnonepithelialcellsparticipating
inbreastcarcinomadevelopment
In addition to the eﬀects of PPARγ ligands on premalig-
nant and malignant breast epithelia, these compounds also
produce profound changes in noncancerous cells. Some of
thesechangesmayberelevanttobreastcarcinomaoutcomes.
For example, PPARγ ligands demonstrate antiangiogenic
eﬀects (reviewed in [40]), including direct suppression of
the vascular endothelial growth factor (VEGF) and the
angiopoietin-1 (Ang-1) gene transcription [61, 62]. On
the other hand, in some noncancerous settings, PPARγ
ligands stimulate angiogenesis [63, 64], thus pointing to
their involvement in remodeling tumor vessels rather than
in suppressing angiogenesis per se.
In vitro experiments suggest that PPARγ ligands act
as diﬀerentiating agents in nonmalignant stromal cells.
Malignant epithelialcells of breast tumors secrete growth
factors and cytokines to prevent the diﬀerentiation of peri-
and intratumoral stromal ﬁbroblasts into mature adipocytes
by downregulation of adipogenic factors such as the C/EBPα
and PPARγ [65]. In turn, underdiﬀerentiated ﬁbroblasts
provide structural and secretory growth promoting support
to tumor tissue [66]. Prolonged treatment with TZDs
stimulates the diﬀerentiation of ﬁbroblasts into adipocytes
instead of myoﬁbroblasts and interferes with transforming
growth factor beta (TGFβ) ﬁbrogenic pathway, particularly,
through attenuation of TGFβ-driven type I collagen protein
production[67].Takentogether,theseeﬀectsofTZDsmayto
some degree counteract desmoplastic proliferative response
promoted by tumor proximity and delay the formation
of the scirrhous component of the breast tumors and the
subsequent spread of tumor cells.
It must be taken into account that an interference of
TZDs with TGFβ signaling is a double-edged sword, since
TGFβ serves as both a tumor suppressor and a tumor4 PPAR Research
promoter depending on tumor developmental stages and
cellular context [19]. During the initial phase of breast
tumorigenesis, the TGFβ signal inhibits primary tumor
development and growth by constraining cell division and
possibly inducing apoptosis [68, 69]. In the later stages of
breast carcinoma development, tumors lose their sensitivity
to TGFβ, but continue overproduction of the hormone.
Excess TGFβ acts upon stromal components of the tumor
promotingthemetastaticprocessthroughdesmoplasticreac-
tion, inhibiting host immune surveillance, and stimulating
invasion and angiogenesis [70]. The outcome of the crosstalk
between TGFβ and PPARγ in breast carcinoma patients
should be dependent on stage of the particular breast lesion.
Last but not least, TZD therapy has been shown to
produce an average weight gain of 4-5kg, which cannot be
explained by ﬂuid retention [71] .T h em a g n i t u d eo fw e i g h t
gain correlates in part with improved metabolic control,
that is, better responders are more prone to increases in
body weight [72]. In turn, weight gain is associated with
a signiﬁcant increase in postmenopausal ER-positive/PR-
positive breast cancer [73, 74]. It remains to be seen whether
TZD-associated increases in adiposity contribute to breast
carcinoma risks similarly to nonspeciﬁc weight gain.
2.3. EffectsofTZDsonbreastcarcinogenesisinvivo
The PPARγ agonist GW7845 delays the development of
mammary tumors in immunocompetent mice treated with
medroxyprogesterone acetate followed by DMBA adminis-
tration by an average of 2 months [75]. In the classic rat
modelofmammarytumorigenesisemployingnitrosomethy-
lurea as a carcinogen, GW7845 also signiﬁcantly reduces
both tumor incidence and tumor weight [76]. Similarly,
troglitazone, alone or in combination with RXR ligands,
prevents the induction of preneoplastic lesions in a mouse
mammary gland organ culture model treated by DMBA
[77]. TZD treatment alone or in combination with ATRA
suppressestumorgrowthfrombreastcarcinomacellsMCF-7
[43]. On the other hand, attempted rosiglitazone chemopre-
vention of breast carcinogenesis in the MMTV-HER-2/neu
transgenicmousemodelproducednoencouragingdata[78].
It is important to note that the mechanisms underlying
various routes of the tumorigenesis in rodent breast diﬀer
substantially [79]; therefore, it is entirely possible that TZDs
may modify outcomes only in some of the models studied. It
is also possible that these eﬀects might be either compound
or dose-speciﬁc.
Recently, a few epidemiological studies have explored
the association of TZD-based diabetes therapy and breast
carcinoma incidence. The largest proﬁled cohort was the one
covered by the Integrated Healthcare Information Services
(IHCISs), Mass, USA, managed care database [80]. The rele-
vantpartofIHCISallowedanalysisofpharmacyanddoctor’s
oﬃce claim data related to 126971 nonelderly USA diabetics
withameanfollowuptimeof16.6months.Importantly,each
individual case of breast carcinoma (N = 513) was matched
to up to ﬁve diabetes controls (cumulative N = 2557) using
matchednestedcase-controldesign.Theadjustedoddsratios
and 95%CI for breast cancer from any exposure to TZD
(mono- or combination therapy) compared to all non-TZD
antidiabetic agents were 0.89 (0.68–1.15) [80]. Thus, neither
abe n e ﬁci aln o rad el et e ri o use ﬀectofTZDsonthelikelihood
of breast carcinoma development was found. It should be
mentioned that the median duration of followup in the
studiedcohortwasrathershortforthedevelopmentofbreast
tumors. Studies following patients for longer periods of time
are warranted.
Another group of researchers analyzed 1003 adult dia-
betic patients participating in a Vermont Diabetes Infor-
mation System (VDIS) study and revealed a signiﬁcant
association between any cancer and the use of any TZD
(OR = 1.59, 95%CI (1.03–2.44), P = .04) [79]. When
TZDs were analyzed by compound, a signiﬁcant association
was found for rosiglitazone (OR = 1.89, 95%CI (1.11–
3.19), P = .02), but not for pioglitazone. Stratiﬁcation
by gender showed a highly signiﬁcant association between
cancer prevalence and TZD use for women (OR = 2.07,
95%CI (1.18–3.63), P = .01) [81] ,b u tn o tf o rm e n .I ti s
important tonote thatthenumberofthepatients enrolledin
thisstudyisnotallowedassessmentoftherisksforindividual
cancers. Nevertheless, the increase of tumor incidence in
TZD using women points at the possible vulnerability of the
breast epithelia.
Slightly more encouraging results were produced in the
recently completed PROactive Study (PROspective piogli-
tAzone Clinical Trial In macroVascular Events). This study
reviewed longitudinal data of 5238 diabetic patients treated
with pioglitazone or with a placebo [82]. The incidence
of breast carcinoma was nonsigniﬁcantly reduced in the
pioglitazone-treated group (3 versus 11 cases in the equally
sized pioglitazone and placebo arms of the study, resp.).
Several attempts to use TZDs as a means of therapy
for breast carcinoma have been made so far. One trial of
TZD as a monotherapy ended 5 months after it started,
because troglitazone was withdrawn from the marker. This
trial—performed in the cohort of patients with advanced
breast cancer refractory to at least one chemotherapy
regimen—resulted in no objective responses [83]. Another
attempt at TZD monotherapy enrolled 38 women with
early-stage lymph node negative breast carcinomas. This
intervention was even shorter as rosiglitazone treatment
(8mg/d) was given between the time of diagnostic biopsy
and deﬁnitive surgery. No signiﬁcant eﬀects on breast
tumor cell proliferation were observed using Ki67 expres-
sion as an endpoint. Interestingly, rosiglitazone treatment
leads to down-regulation of nuclear PPARγ expression,
as demonstrated by immunohistochemistry. Additionally,
rosiglitazone intervention resulted in an increase of serum
adiponectin concentrations (P<. 001). Serum adiponectin
negatively regulates breast cancer growth [84] and inhibits
angiogenesis by suppression of endothelial cell proliferation
and migration [85]. The potential therapeutic implications
of rosiglitazone modulation of adiponectin levels require
further study.
3. PPARα LIGANDS
The nuclear receptor PPARα regulates lipid metabolism
in general and β-oxidation of fatty acids in particular.Ancha Baranova 5
Its gene, PPARA, expresses mainly in tissues with high
energy requirements, particularly in the skeletal muscle, the
heart, and the liver [86]. PPARα is activated by a number
of natural ligands, including various derivatives of fatty
acids and leukotriene B4, and by common lipid-lowering
drugs, particularly fenoﬁbrate and gemﬁbrozil. Activated
PPARα exerts beneﬁcial eﬀects on lipid metabolism, raising
cardioprotective high-density lipoprotein (HDL) cholesterol
and lowering cardiovascular mortality [87]. In addition,
activation of PPARα may limit inﬂammation, both in the
vessel endothelium and in other tissues as well as inhibit the
ﬁbrotic response. The apparent uniformly beneﬁcial action
of PPARα agonists prompted the development of a number
of these compounds. Among them, some exert dual aﬃnity
to PPARα and PPARγ. Dual agonists hold considerable
promise in the management of insulin resistance, serving
as major confounders for cardiovascular diseases and other
comorbidities associated with metabolic syndrome.
Experimental data describing the eﬀects of PPARα ago-
nists on tumor initiation and progression are limited. Long-
term administration of PPARα ligands cloﬁbrate and WY-
14643 in the rodent model induces hepatocellular neoplasms
includingadenomasandcarcinomas[88].PPARαsuppresses
apoptosis in liver tissue in response to various peroxisome
proliferator carcinogens, especially in the presence of TNFα
[89]. As levels of TNFα are substantially elevated in obesity
and in metabolic syndrome, it could be hypothesized that
hepatocarcinogenesis may be an issue for long-term ﬁbrate
medicated patients. So far, epidemiological observations in
ﬁbrate treated populations have not produced any evidence
that ﬁbrates are associated with elevated risk of liver cancer
or any other neoplasms in humans. As PPARα-humanized
mice are resistant to hepatocarcinogenic eﬀects of ﬁbrates, it
seemsthattheresponse described in mousemodels is species
speciﬁc [90].
Studies of the nonhepatic tumorigenesis models indicate
that in other tissues PPARα agonists exert antiproliferative
eﬀects [91]. In the mouse model of skin carcinogenesis, an
animal topically treated with PPARα ligands exhibited an
approximately 30% lower skin tumor yield compared with
mice treated with vehicle, thus indicating that the activation
of PPARα may suppress the earliest stages of tumor devel-
opment [92]. Additionally, PPARα ligands possess strong
antiangiogenic properties, as they suppress endothelial cell
proliferation and VEGF production, upregulate TSP-1 and
endostatin, and inhibit neovascularization [93, 94].
Studies concerning PPARα activation in breast carcino-
mas are scarce. It is known that PPARα is expressed and
dynamically regulated in both ER-positive (MCF-7) and ER-
negative (MDA-MB-231) human breast cancer cells. PPARα
activation signiﬁcantly increases proliferation of both cell
lines, and this increase is proportional to the endogenous
level of PPARα [95]. On the other hand, one recent study
pointed at PPARα as a possible contributor to the growth
inhibitory eﬀect of n-6 PUFA arachidonic acid exerted in the
same pair of breast carcinomas cell lines [96].
PPARα also reduces the sensitivity of MCF-7cells to
histone deacetylase inhibitors [97]. Interestingly, there is
an inverse relationship between mean PPARα and ERα
mRNA levels in ER-positive breast cancer cells [97]. These
observations point to the possible involvement of PPARα
activation in mammary gland tumorigenesis and vouch for
a longitudinal study of breast carcinoma incidence and
progression in patients using ﬁbrate therapy.
4. PPARδ LIGANDS
The nuclear receptor PPARδ, also known as PPARβ,i s
expressed ubiquitously. It controls a number of physiological
functions, particularly cell proliferation and diﬀerentiation
as well as inﬂammation and energy homeostasis [22].
Interestingly,PPARδ istheonlyPPARisoformthatmaintains
repressor activity when bound to DNA. When unligated,
PPARδ can act as an intrinsic transcription repressor and
inhibit the trans-activation activity of other PPARs [98].
It was suggested that PPARδ serves as a gateway receptor
capable of modulating PPARα and PPARγ activity [98].
The ligand binding pocket domain of PPARδ is larger than
that of other PPARs and is believed to accommodate the
binding of various fatty acids and their derivatives [99]. A
number of synthetic agonists are being developed for the
same purpose with nanomolar aﬃnities [100, 101], although
none is currently marketed for clinical use in humans yet.
The physiological eﬀects of activated PPARδ have been
studied extensively [22, 102]. The results of these studies
suggest that sooner or later high-aﬃnity PPARδ synthetic
drugs which uniquely target multiple components of the
metabolic syndrome, including obesity, insulin resistance,
hyperglycemia, dyslipidemia, and atherosclerosis will enter
the market. Some of these compounds are already being
subjected to phase I/II clinical trials. In light of this fact, it is
important to establish experimental systems allowing rapid
evaluation of the potential carcinogenic or chemopreventive
eﬀects of the synthetic PPARδ ligands. Given that the
prevalence of the metabolic syndrome and comorbidities
associated with the disease is on the rise in both developed
and developing countries, it is extremely important to watch
for possible eﬀects of anticipated chronic exposure to PPARδ
ligands upon common types of cancer, particularly upon
breast carcinoma.
Alarmingly, PPARδ selective agonists stimulate the
growth of the hormone-dependent breast carcinoma cell
lines T47D and MCF-7. In T47D cells, activation of PPARδ
stimulates expression of the proliferation marker Cdk2. In
addition, an increase in the production of both VEGF and
its receptor, FLT-1 has been noted, suggesting that PPARδ
may initiate an autocrine loop for cellular proliferation
and possibly angiogenesis. Similar pro-proliferative eﬀects
of activated PPARδ have been observed in endothelial cell
cultures [103]. Further studies of angiogenic and growth-
inducing properties of PPARδ agonists in breast epithelia are
warranted.
5. GENERAL REMARKS
It should be mentioned that breast carcinoma is not a
single disease entity, but rather an extremely polymorphic
spectrumofneoplasticpathologieswhicharefairlydiversein6 PPAR Research
More data warranted
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Figure 1: A summary of inﬂuence of PPAR ligands on the process of breast carcinogenesis.
their molecular portraits. It is likely that both chemopreven-
tion and treatment by PPAR ligands as well as their possible
tumorigenic side eﬀects will be selective to particular molec-
ular subtypes of tumor, or will be relevant to certain stages
of carcinoma progression (Figure 1). Therefore, much larger
cohorts of patients followed for longer periods of time will
have to be studied in order to reveal statistically signiﬁcant
modiﬁcations of the disease’s outcome. Chemoprevention
studies of this type are prohibitively expensive, for example,
the recently completed National Surgical Adjuvant Breast
and Bowel Project Study of Tamoxifen and Raloxifene
(STAR) trial with an endpoint of cancer incidence required
the enrollment of 19747 subjects from near 200 clinical
centers throughout North America took 8 years before initial
data analysis, and cost approximately $200 million [104,
105].Beforeinitiatinglarge-scaleeﬀorts,acomparativestudy
of the molecular portraits of breast carcinomas developed in
chronic TZD users and in the general population needs to
be completed. This kind of study could be performed using
m i c r o a r r a y sa sap r i m a r yp r o ﬁ l i n gm e a n sw h i c hs h o u l db e
complemented by validation eﬀorts through the methods of
immunohistochemistry, in situ hybridization of mRNA, and
phosphoproteomics.Thedesignofthisstudycouldbeachal-
lenge due to the diﬃculties with proper matching of groups
compared and with eliminating common confounders. One
of the possible ways to overcome this problem is to proﬁle
both malignant and normal breast epithelia samples of
current TZD users to that of recently diagnosed diabetics
never exposed to TZDs. Conﬁrmed diﬀerences between the
molecular portraits of tumors which initiated or progressed
despite an exposure to PPAR ligand and subtype-matched
tumors that arose on TZD free background may give some
important clues to the design of a clinical trial aimed at
chemoprevention-related endpoints.
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